Zentalis Pharmaceuticals, Inc. (ZNTL)

Market Cap	213.08M
Revenue (ttm)	40.56M
Net Income (ttm)	-179.28M
Shares Out	71.27M
EPS (ttm)	-2.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,149,111
Open	3.060
Previous Close	3.050
Day's Range	2.913 - 3.065
52-Week Range	2.660 - 18.070
Beta	1.74
Analysts	Buy
Price Target	10.50 (+251.17%)
Earnings Date	Nov 12, 2024

About ZNTL

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 3, 2020
• Employees: 124
• Stock Exchange: NASDAQ
• Ticker Symbol: ZNTL
• Website: https://zentalis.com

Analyst Forecast

According to 8 analysts, the average rating for ZNTL stock is "Buy." The 12-month stock price forecast is $10.5, which is an increase of 251.17% from the latest price.

Price Target

$10.5

(251.17% upside)

Analyst Consensus: Buy